Table 2 Top 10 treatment-Related Adverse Events (TRAEs) ranked by frequency of G3 toxicitya
From: Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Adverse events | Grade 1 | Grade 2 | Grade 3 |
|---|---|---|---|
Any Treatment Related Adverse Event | 0(0%) | 11(44%) | 13(52%) |
Neutrophil count decreased | 3(12%) | 7(28%) | 6(24%) |
Fatigue | 7(28%) | 7(28%) | 4(16%) |
Anemia | 6(24%) | 10(40%) | 2(8%) |
Aspartate aminotransferase increased | 4(16%) | 0(0%) | 2(8%) |
Platelet count decreased | 10(40%) | 1(4%) | 1(4%) |
Alanine aminotransferase increased | 3(12%) | 0(0%) | 1(4%) |
Hepatic infection | 0(0%) | 0(0%) | 1(4%) |
Hypermagnesemia | 0(0%) | 0(0%) | 1(4%) |
Hypertension | 0(0%) | 0(0%) | 1(4%) |
Diarrhea | 13(52%) | 3(12%) | 0(0%) |
